ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
IPO Year:
Exchange: NASDAQ
Website: chromadex.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2022 | Outperform → Perform | Oppenheimer | |
| 8/11/2022 | $6.00 → $2.40 | Buy → Neutral | B. Riley Securities |
| 3/10/2022 | $16.00 → $8.00 | Buy | B. Riley Securities |
| 3/8/2022 | $7.00 | Buy | ROTH Capital |
| 8/4/2021 | $11.00 → $12.00 | Buy | HC Wainwright & Co. |
4 - ChromaDex Corp. (0001386570) (Issuer)
The gold standard in NAD+ supplementation, Niagen® is a key ingredient for supporting cellular health and promoting healthy aging in Longevity.Technology's new supplement ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announces that its flagship patented nicotinamide riboside (NR) ingredient, Niagen®, is the hero ingredient in Longevity.Technology's inaugural supplement called Longevity.Technology® LONGEVITY. Designed to support a healthier, longer life, the supplement includes Niagen, the gold standard ingredient for enhancing NAD+ levels and optimizing cellular health. Longevity.Technology,
National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) products, Niagen® IV, now accessible at over 200 Restore Hyper Wellness locations across the United States. This represents a major milestone, making Niagen IV—a significant advancement in intravenous NAD+ therapy—more widely accessible to wellness enthusiasts looking to enhance cellular health and extend their healthspan. Available in oral and IV
Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY. Delivered strong gross margin of 63.5%, up 210 basis poi
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Thursday, October 31, 2024, at 4:30 p.m.
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, November 6, 2024 at 4:30 p.m. ET. to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Wednesday, November 6, at 4:30 p.m. ET. Participants should call in
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will be participating at the 17th Annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel, California on October 29th, 2024. The event is expected to feature 150 companies, presenting in half-hour increments, as well as private 1:1 meetings. ChromaDex's Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, are scheduled to present on October 29th at 2:00pm Pacific Time (5:00pm Eastern Time). ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. For those in
This award recognizes Dr. Nkrumah-Elie's dedication to advancing scientific excellence for ChromaDex's leading external research program and mentorship in the dietary supplement industry ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that Radicle Science and Council for Responsible Nutrition (CRN) honored Yasmeen Nkrumah-Elie, Ph.D, ChromaDex's Global Director of External Research, as the winner of the inaugural Trailblazing Woman Award. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241015810330/en/Yasmeen Nkrumah-Elie, Ph.D
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference. Wesley Yu, Vice President of Finance at ChromaDex, and Mr. Fried will also host virtual one-on-one meetings with investors. Company Webcast The webcasted fireside chat will take place at 1:15 PM ET on Tuesday, October 1, 2024. The webcast can be accessed at https://app.webinar.net/7yrd0odReoK or on the Company's website at ch
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public markets through investor relations. Effective October 21, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Mr. Fried commented, "We are very pleased to welcome Ozan to the ChromaDex team. His ambitious work ethic and impressive professional background will help us to embark on this critical next phase of develo
Commemorating a quarter of a century with an exclusive 25% off lifelong subscription on Tru Niagen® ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, proudly announces its 25th anniversary. For a quarter of a century, ChromaDex has been at the forefront of analytical chemistry and scientific innovation, dedicated to unlocking the full potential of NAD+ to promote healthy aging and enhance the quality of life for people around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909499862/en/ To celebrate this milestone, ChromaDex is off
Oppenheimer downgraded ChromaDex from Outperform to Perform
B. Riley Securities downgraded ChromaDex from Buy to Neutral and set a new price target of $2.40 from $6.00 previously
B. Riley Securities reiterated coverage of ChromaDex with a rating of Buy and set a new price target of $8.00 from $16.00 previously
ROTH Capital initiated coverage of ChromaDex with a rating of Buy and set a new price target of $7.00
HC Wainwright & Co. reiterated coverage of ChromaDex with a rating of Buy and set a new price target of $12.00 from $11.00 previously
HC Wainwright & Co. reiterated coverage of ChromaDex with a rating of Buy and set a new price target of $11.00 from $16.00 previously
HC Wainwright & Co. reiterated coverage of ChromaDex with a rating of Buy and set a new price target of $16.00 from $7.00 previously
Oppenheimer initiated coverage of ChromaDex with a rating of Buy and set a new price target of $9.00
B. Riley resumed coverage of ChromaDex with a rating of Buy and set a new price target of $18.00 from $7.00 previously
3 - ChromaDex Corp. (0001386570) (Issuer)
4 - ChromaDex Corp. (0001386570) (Issuer)
3 - ChromaDex Corp. (0001386570) (Issuer)
4 - ChromaDex Corp. (0001386570) (Issuer)
4 - ChromaDex Corp. (0001386570) (Issuer)
4 - ChromaDex Corp. (0001386570) (Issuer)
3 - ChromaDex Corp. (0001386570) (Issuer)
4 - ChromaDex Corp. (0001386570) (Issuer)
4 - ChromaDex Corp. (0001386570) (Issuer)
4 - ChromaDex Corp. (0001386570) (Issuer)
Results from the at-home test kit are available to HCPs and their patients through 1healthChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit*, now available exclusively through the company's healthcare practitioner (HCP) channel. This innovative test kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, helping them create more personalized and effective patient protocols using ChromaDex's NAD+-boosting HCP products, Tru Niagen® and Niagen+.
-SEC Filing
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness, and REVIV
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.
NR improved the six-minute walking distance and treadmill walking time for those with PAD
Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.
Shares of GameStop Corp. (NYSE:GME) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to sell up to 75 million shares. GameStop released its first-quarter 2024 results early Friday ahead of its scheduled June 11 date. The company reported net sales of $881.8 million, down from $1.237 billion year-over-year. The net sales total missed a consensus estimate of $995.3 million. The company reported a loss of 12 cents per share, missing the estimate of a loss of 9 cents per share, according to data from Benzinga Pro. GameStop shares dipped 22.5% to $36.07 on Friday. Here are some other stocks moving in today
SC 13D/A - ChromaDex Corp. (0001386570) (Subject)
SC 13D/A - ChromaDex Corp. (0001386570) (Subject)
SC 13D/A - ChromaDex Corp. (0001386570) (Subject)
SC 13G - ChromaDex Corp. (0001386570) (Subject)
SC 13D/A - ChromaDex Corp. (0001386570) (Subject)
SC 13D/A - ChromaDex Corp. (0001386570) (Subject)
SC 13G/A - ChromaDex Corp. (0001386570) (Subject)
SC 13D/A - ChromaDex Corp. (0001386570) (Subject)
SC 13D/A - ChromaDex Corp. (0001386570) (Subject)
SC 13G/A - ChromaDex Corp. (0001386570) (Subject)
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public markets through investor relations. Effective October 21, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Mr. Fried commented, "We are very pleased to welcome Ozan to the ChromaDex team. His ambitious work ethic and impressive professional background will help us to embark on this critical next phase of develo
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. Effective today, July 22, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Carlos Lopez is a distinguished legal professional and executive leader with expertise in the dietary supplements industry. Prior to joining ChromaDex, he served as the Vice President, General Counsel at The Vitamin Sh
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes. This inclusion will be effective at the opening of U.S. equity markets on Monday, July 1, 2024, based on the preliminary list of additions posted on Friday, May 24, 2024. Rob Fried, CEO of ChromaDex and Founder of Tru Niagen commented, "Joining the Russel
This partnership positions Tru Niagen for accelerated global expansion given nearly 90% of iHerb sales are outside of the U.S. ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world's number one online destination for health and wellness, iHerb, as the newest retail partner to distribute Tru Niagen globally. iHerb is on a mission to make health and wellness accessible to all offering the best brands in the industry and has established a strong international presence, with nearly 90% of sales generated outside of the United States. iHerb has a global audience larger than Vitacost, VitaminShoppe, and GNC combined, proudl
Globally acclaimed authority on aging to further research on the potential benefits of nicotinamide riboside (NR) and age-related conditions. ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced it has appointed Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. to its Scientific Advisory Board (SAB). Dr. Bohr is one of the world's most published researchers on aging and neurodegenerative disease with over 590 journal publications. For the past 30 years, Dr. Bohr served as Chief of the Laboratory of Molecular Genetics at the National Institute on Aging, which is part of the National Institute of Health (NIH). In 2014, Dr. Bohr initiated research throug
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023. Gerber served as Senior Vice President, Finance / Interim Chief Financial Officer of ChromaDex since August 11, 2022, and prior to that was the Vice President of Finance and Investor Relations of ChromaDex since September 17, 2018. Gerber has over 20 years of diverse experience in investment management, investor relations and finance, including strategic planning, operational efficiency programs, and capital market transactions. "We are delighted to start the new year by celebrating Brianna'
Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture BOSTON, Aug. 24, 2022 /PRNewswire/ -- Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the appointment of Frank Jaksch as the company's chief executive officer. Jaksch founded, was the longtime CEO and presently serves as Board Chair of health and wellness company ChromaDex, manufacturer of popular NAD product, Tru Niagen (NASDAQ:CDXC).
ChromaDex Corp. (NASDAQ:CDXC) today announced that it has appointed two new members to its Board of Directors: Kristin Patrick, Executive Vice President and Chief Marketing Officer of Claire's Inc., and Ann Cohen, Executive Vice President and Chief Financial Officer of The Institute of Internal Auditors (The IIA). "We welcome Ms. Patrick and Ms. Cohen to our distinguished ChromaDex Board of Directors," said Rob Fried, CEO of ChromaDex. "Ms. Patrick has overseen some of the world's most recognizable and respected consumer brands, and Ms. Cohen is an executive with significant financial expertise and of strong personal integrity. We are excited and honored to be working with them both." As
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer. Karam has spent his career driving consumer businesses across multiple geographies and cultures, including scaling direct-to-consumer operations across digital, social, and traditional marketing platforms, as well as launching and scaling product innovation. Prior to joining ChromaDex, Karam led the local brand portfolio for Nestlé Waters North America with over $3 billion in annual revenues. Previously, Karam was based in the Nestlé Headquarters in Switzerland where he conceived and led a global relaunch of the KitKat brand, and redefined the global product innovation pipeline. He a
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed David L. Katz, MD, MPH, FACPM, FACP, FACLM - CEO of Diet ID, Inc, founder and former director of Yale University’s Yale-Griffin Prevention Research Center and past president of the American College of Lifestyle Medicine, to its Scientific Advisory Board (SAB). Dr. Katz is a leading expert in nutrition, health promotion and the prevention of chronic disease through his work as a researcher, author and clinician. As CEO of Diet ID, Dr. Katz oversees a team working to make diet a vital sign, leveraging an advance in dietary assessment. He also serves as president for True Health Initiative,
Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY. Delivered strong gross margin of 63.5%, up 210 basis poi
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Thursday, October 31, 2024, at 4:30 p.m.
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, November 6, 2024 at 4:30 p.m. ET. to discuss its financial results for the third quarter, which ended September 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Thursday, October 31, 2024. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the third quarter 2024 results and provide a general business update on Wednesday, November 6, at 4:30 p.m. ET. Participants should call in
Total net sales of $22.7 million, up 12% year-over-year, gross margin of 60.2%, lower operating expenses, resulting in approximately breakeven net loss and positive Adjusted EBITDA of $1.6 million for the three months ended June 30, 2024. ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2024. Second Quarter 2024 Financial and Recent Operational Highlights Total net sales were $22.7 million, with $18.6 million from Tru Niagen®, up 12%, and 10%, respectively, from the prior year quarter. Solid gross margin of 60.2% and a $0.7 million reduction in total operating expenses from the prior year quarter. Net loss and loss per share were approxi
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, August 7, 2024 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the second quarter 2024 results and provide a general business update on Wednesday, August 7, at 4:30 p.m. ET. Participants should call
Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%. ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024. First Quarter 2024 Financial and Recent Operational Highlights Total net sales were $22.2 million, with $17.4 million from Tru Niagen®. Solid gross margin of 60.7%, an increase of 80 basis points, compared to 59.9% from the prior year quarter. Sales and marketing expense as a percentage of net sales was 30.4%, an improvement of 450 basis poin
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the first quarter 2024 results and provide a general business update on Wednesday, May 8, at 4:30 p.m. ET. Participants should call in at least 10 minu
Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows. ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Total net sales of $21.2 million, with $17.6 million from Tru Niagen®, up 1% and 9%, respectively, from the prior year quarter. Delivered strong gross margin of 61.0%, an increase of 380 basis points, compared to 57.2% from the prior year quarter. A
ChromaDex Corp. (NASDAQ:CDXC) ("the Company"), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss fourth quarter 2023 results and provide a general business update on Wednesday, March 6, at 4:30 p.m. ET. Participants should call in at least 10 minutes prior to t
Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023. ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2023. Third Quarter 2023 and Recent Highlights Total net sales were $19.5 million, with $17.4 million from Tru Niagen®, up 14% and 19% from the prior year quarter, respectively. Strong gross margin of 61.4%, an increase of 160 basis points, compared to 59.8% from the prior year quarter. Sales and marketing expense as a percentage of net sales was 31.0%, an improve
424B3 - ChromaDex Corp. (0001386570) (Filer)
8-K - ChromaDex Corp. (0001386570) (Filer)
8-K - ChromaDex Corp. (0001386570) (Filer)
10-Q - ChromaDex Corp. (0001386570) (Filer)
8-K - ChromaDex Corp. (0001386570) (Filer)
8-K - ChromaDex Corp. (0001386570) (Filer)
8-K - ChromaDex Corp. (0001386570) (Filer)
10-Q - ChromaDex Corp. (0001386570) (Filer)
8-K - ChromaDex Corp. (0001386570) (Filer)
8-K - ChromaDex Corp. (0001386570) (Filer)